GlassScriptPhysician profile
Douglas D Dykman
NPI 1942232939
$988.70
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2021: $29.45.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.75 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.58 | 2019 | |
| Janssen Biotech, INC. | $111.52 | 2019 | |
| Pfizer INC. | $97.64 | 2019 | |
| Biofire Diagnostics, LLC | $68.05 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.45 | 2019 | |
| Qol Medical, LLC | $25.20 | 2019 | |
| Braintree Laboratories, INC. | $23.06 | 2019 | |
| Echosens North America, INC. | $20.01 | 2019 | |
| Shionogi INC | $19.81 | 2019 | |
| Ucb, INC. | $15.43 | 2019 | |
| Gilead Sciences, INC. | $14.43 | 2019 | |
| Dova Pharmaceuticals | $13.42 | 2019 | |
| Vivus LLC | $11.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Dykman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.